At present, chemotherapy is a clinically important treatment method for malignant tumors. However, the efficacy of chemotherapy is usually unsatisfying. The main reason is that tumor cells develop multidrug resistance (MDR). One principal mechanism of MDR is the overexpression of Pglycoprotein (Pgp), which can pump a variety of chemotherapy drugs out of the tumor cells, causing decreased intracellular concentrations of the drugs and inducing MDR. Studies have shown that clinically used chemotherapy drugs play roles mainly through inducing cell apoptosis [1] . Recent studies have found that the inhibition of tumor cell apoptosis has also led to MDR in tumor cells [2] . Many factors related to apoptosis affect the emergence of MDR together with Pgp.
It has been shown that imatinib induces tumor cell apoptosis and reverses MDR. 5bromotetrandrine (BrTet) is a brominated product of Traditional Chinese Medicine reversed agent tetrandrine, which has a higher capacity for reversing drug resistance. Here, we used imatinib and BrTet alone and in combination to detect whether there was a synergistic effect on the reversal of drug resistance, and whether the expression of mdr1 mRNA and Pgp were related to tumor cell apoptosis.
Fetal bovine serum (FBS) The K562/A02 cells were cultured in a medium containing 1 滋 g/mL Adriamycin, and 2 weeks before treatment, the cells were cultured in a medium without Adriamycin. All cell lines were cultured in RPMI1640 containing 10% FBS, 100 U/mL penicillin and 100 滋 g/mL streptomycin at 37益 in the humidified atmosphere of a 5% CO 2 incubator. The cells were subcultured every 23 days.
The logarithmic (log) phase of the K562/A02 and K562 cells were diluted to 2 伊 Each concentration repeated 3 times. Cells without MDRreversing agents served as the control groups. After 48 h of treatment, 20 滋 L of MTT (5 mg/mL) was added to each well and cultured for another 4 h. Lipids were discarded and 150 滋 L of DMSO was added to each well and oscillated for 10 min. Absorbency ( ) value was measured at 490 nm. The cell proliferation inhibition rate was calculated by following formula: cell proliferation inhibition rate = (1 value of the experimental group/ value of the control group) 伊 100% . All experiments were repeated 3 times, and the average values were as the final results.
Logphase cells were treated with 0.0625 滋 mol/L of imatinib and 0.5 滋 mol/L of BrTet alone or combined for 1 h. Different concentrations of DNR were added according to the study design. Each concentration was repeated 3 times. Without MDRreversing agents, DNR and cells served as the control groups. Treatment and measurement of the control groups were the same as the experimental groups. Cell proliferation inhibition was calculated according to subsection formula above mentioned.
An integrated method was used to calculate the half maximal inhibitory concentration (IC 50 ) according to the cell proliferation inhibition rate. Multiples of reversal = IC 50 of drugresistant cells/IC 50 of cells treated with MDRreversing agents. All experiments were repeated 3 times, and the average values were the final results.
The logarithmic phase of K562/A02 cells was adjusted to 2 伊 10 5 cells/mL. The negative control group did not have any drugs added. The experimental groups were divided into 6 groups as follows: (1) the DNR group, (2) the imatinib group, (3) the BrTet group, (4 ) the DNR + imatinib group, (5) the DNR + BrTet group, and (6) DNR + imatinib + BrTet group. After 48 h of treatment, the cells were collected, washed with 4益 chilled phosphate buffered saline (PBS) and resuspended with 1 mL of a buffer with Ca
2+
. A volume of 10 滋 L of Annexin VFITC was added to each group. Blank and FITC were used as controls. Cells were incubated at room temperature for 15 min and protected from the light. After washing, the cell apoptosis rate was measured by flow cytometry.
The K562/A02 cells were adjusted to 2 伊 10 5 cells/mL and treated with the drugs. Cells were collected after treatment for 48 h. A volume of 1 mL of TRIzol was used for total RNA extraction. Reverse transcriptase for the synthesis of complementary DNA (cDNA) was supplied by TaKaRa LA PCR TM Kit Ver.2.1 and cDNA was synthesized according to the kit. The amount of total RNA was 2 滋 g and the total volume was 25 滋 L. The reverse conditions were as follows: 30益 for 10 min, 42益 for 30 min, 99益 for 5 min, and 5益 for 5 min. The forward primer was 5'TTGTTTGCCACCACGATA3' and reverse primer was 5'GAA CCACTGCTTCGCTTT3'. The cycling conditions for amplification were as follows: the initial denaturation at 94益 for 2 min, then 30 cycles at 94益 for 30 s, 56益 for 30 s, and 72益 for 40 s, followed by a final extension at 72益 for 5 min. The density of the bands were analyzed after electrophoresis. The relative level of expression of the target gene was indicated by the ratio of the density of the target gene PCR product to the 茁 actin PCR product.
Cells were treated with 0.0625 滋 mol/L of imatinib and 0.5 滋 mol/L of BrTet alone and in combination and collected. Protein was extracted and protein concentrations were determined by the Bradford method. Equal amounts of cell extracts were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDSPAGE) and transferred to a polyvinylidene fluoride (PVDF) membrane and blocked for 4 h at room temperature. Mouse antihuman Pgp antibody was used as the first antibody and the membranes were incubated at 4益 overnight. After washing the membrane, a secondary antibody (goat antimouse IgG antibody) was added and incubated for 1 h at room temperature. The unbound secondary antibody was washed out, then a fresh visualization reagent was added and the reaction was terminated after 20 min. 茁 actin served as the control. The experimental data was indicated by the ratio of the density of the target protein to 茁 actin. Each experiment was repeated 3 times, and the average values were the final results.
Statistical analysis was performed using SPSS version 13.0, and data were shown by mean ± standard deviation. The effect of the predictive variables was evaluated by a univariate model, and < 0.05 was considered statistically significant. The IC 50 of DNR for K562 and K562/A02 cells were 12.50 mg/L and 0.36 mg/L, respectively. The multiple of drug resistance was 34.7. After the K562/A02 cells were treated with imatinib and BrTet alone or in combination, the IC 50 was 5.69 mg/L, 5.41 mg/L, and 2.19 mg/L, respectively. The multiples of reversal were 2.19, 2.31, and 5.71, respectively. Between the singleagent treatment groups and the combined treatment groups, the differences were statistically significant ( < 0.05) (Figure 1 ). MDRreversing agents alone or combination had no effect on the toxicity of K562 cells induced by DNR ( > 0.05) (Figure 2 ).
Concentrations
The rate of cell apoptosis of the K562/A02 cells was 5.47 ± 0.60. DNR, imatinib, and BrTet alone did not increase the rate of apoptosis ( > 0.05). DNR in conjunction with the MDRreversing agents significantly increased the rate of cell apoptosis. Among them, the combined group with DNR, imatinib, and BrTet was the most significant ( < 0.01) (Figure 3 ).
After treatment with imatinib and BrTet separately, the average mRNA expression level of mdr1 was lower than the control group in K562/A02 cells (the K562 group was 0.23 依 0.03, the K562/A02 group was 0.96 依 0.01, the K562/A02 + imatinib group was 0.65 依 0.02, and the K562/A02 + BrTet group was 0.64 依 0.01, < 0.01). The grayscale values of the imatinib and BrTet combination group was 0.25 依 0.03, which decreased significantly compared to the singleagent groups ( < 0.01) (Figure 4 ).
The level of Pgp expression of sensitive K562 cells was 0.20 MDR means that after exposure to a class of drugs, tumor cells produce drug resistance to a variety of drugs with the same or different chemical structures and functional mechanisms. Current studies have shown that the mechanisms of MDR are complex [3] . The traditional mechanism of drug resistance was that the membrane glycoprotein Pgp bound with ATP on the cellular surface, which mediated the efflux of chemotherapeutic drugs in tumor cells. Recent studies have found that antiapoptosis is another mechanism of drug resistance in tumor cells [4] . Tumor cells may produce antiapoptotic factors to reduce cell apoptosis. Antiapoptosis and Pgp together triggered the development of MDR.
K562/A02 cells were an MDR cell line, which was induced by treating K562 cells with Adriamycin. Pgp expression was positive in K562/A02 cells [5] , and the basic phenotype of K562 was maintained. Therefore, we used K562 and K562/A02 cell lines as the experimental targets.
Since the mechanisms of MDR are complex, the results of targeting single mechanisms for reversing drug resistance are usually not ideal. The efficacy of targeting multiple mechanisms that reverse drug resistance may yield better prospects [6] . Thus, we are committed to looking for more efficient MDRreversing agents. The present study showed that 0.0625 滋 mol/L and lower concentrations of imatinib did not show direct cytoxicity on K562 or K562/A02 cells; 0.5 滋 mol/L and lower concentrations of BrTet did not either. Single and combined concentrations of 0.0625 滋 mol/L of imatinib and 0.5 滋 mol/L of BrTet significantly enhanced cell apoptosis induced by DNR in K562/A02 cells. More marked effects were found in the combination of imatinib and BrTet, which enhanced cell apoptosis induced by DNR in K562/A02 cells correspondingly.
P210 was overexpressed in K562 cells with an abnormally high level of tyrosine kinase activity, which activated a series of antiapoptosis signal transduction pathways, such as RASMAPK, PBK/AKT, and JAK/STAT. The antiapoptotic ability was further strengthened in the K562 cells [7] , the chemotherapeutic drug sensitivity decreased, and antiapoptosis for multiple drugs was produced [8] . Wang [9] . found that BrTet, as a tetrandrine brominated product, had a greater ability to reverse drug resistance than tetrandrine. One of the main mechanisms was that BrTet increased the sensitivity to chemotherapeutic drugs. As shown by flow cytometry, the imatinib, BrTet, and DNR singleagent groups did not increase the rate of cell apoptosis for K562/A02 cells. While treated with the combinations, the rate of cell apoptosis increased significantly, and the tripledrug combination group was the highest.
Imatinib is a selective inhibitor of bcrabl and other tyrosine kinases, including stem cell factor receptor ckit (CD117) and platelet derived growth factor receptor (PDGFR) [10] . Previous studies have shown that decreased the expression of bcrabl in K562 cells may be associated with the reversal of drug resistancel [11] . Wang [9] . also found that another mechanism of drug resistance reversed by BrTet decreased the expression of Pgp and increased the cellular drug concentration. Therefore, we presumed that both imatinib and BrTet could reverse drug resistance, and the mechanism was not only related to cell apoptosis, but also related to Pgp expression. As shown by RTPCR, after treatment with imatinib and BrTet separately, the expression of Pgp decreased, and decreased more significantly in combination, showing a synergic effect. Additionally, Western blot analysis showed that the protein expression of Pgp also decreased, as did mRNA expression, which confirmed that the combination of imatinib and BrTet was significantly better than the single drug.
In summary, imatinib and BrTet reversed MDR of K562/A02 cells induced by DNR, which was not only related to decreasing mRNA and protein expressions of mdr1, but also related to increased drug sensitivity and cell apoptosis. However, the mechanism needs to be studied further. Our study supplied a good basis for multiple mechanisms of MDRreversing agents for the treatment of relapsed and refractory leukemia. 
